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ABSTRACT 
Purpose. Pharmacoepidemiologic studies using electronic health record (EHR) data could 
serve an important role in assessing safety and effectiveness of direct-acting antiviral (DAA) 
therapy for chronic hepatitis C virus (HCV) infection, but the validity of these data needs to 
be determined. We evaluated the accuracy of pharmacy fill records in the national Veterans 
Health Administration (VA) Corporate Data Warehouse (CDW) as compared to facility-level 
EHR. 
Methods. Patients prescribed a DAA regimen at five VA sites between 2014-2016 were 
randomly selected and reviewed. A random sample of patients with chronic HCV infection 
without evidence of HCV treatment during the study period also underwent chart review. 
We calculated positive predictive value (PPV) and negative predictive value (NPV) overall 
and by site. 
Results. Of the 501 patients who received a total of 2,416 prescriptions, 494 were validated 
using data extracted from CDW six months after the study period, yielding a PPV of 98.6% 
(95% confidence interval [CI], 97.6%-99.6%). Of the 100 patients with chronic HCV 
infection without prescriptions for HCV treatment, 99 were confirmed not to have received 
antiviral treatment (NPV, 99.0%; 95% CI, 97.1%-100%). 
Conclusions. These findings provide assurance to researchers who use national VA CDW 
data for retrospective cohort studies that the CDW contains accurate information on HCV 
therapies in the modern treatment era. 
 
Keywords (3-10 in alphabetical order): antivirals; direct-acting antiviral; hepatitis C; 
observational data; pharmacy; validation  
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ABBREVIATIONS 
CDW  Corporate Data Warehouse 
Choice Veterans Choice Program 
DAA  direct-acting antiviral 
DC  Washington, DC 
EHR  electronic health record 
HBV  hepatitis B virus 
HCV  hepatitis C virus 
ID  infectious disease 
LA  Los Angeles 
NPV  negative predictive value 
PPV  positive predictive value 
RNA  ribonucleic acid 
US  United States 
VA  Veterans Health Administration 
VACS  Veterans Aging Cohort Study 
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INTRODUCTION 
Hepatitis C virus (HCV) infection is a major public health priority in the United States (US), 
with an estimated 2.7 million chronically infected residents [1]. New direct-acting antiviral 
(DAA) agents for the treatment of chronic HCV were approved by the US Food and Drug 
Administration in 2014 [2, 3]. Clinical trials demonstrated that >90% of patients achieve viral 
cure with typically no more than 12 weeks of treatment [2, 4]. However, clinical trials often 
underrepresent individuals with pre-existing conditions, older patients, and minorities, thus 
attenuating their generalizability to routinely treated populations. Observational data could 
serve an important role in pharmacoepidemiologic studies assessing the safety and 
effectiveness of modern therapies for chronic HCV infection [5].  
 
The Veterans Health Administration (VA) is the largest provider of chronic HCV care in the 
US, with an HCV seroprevalence of 5.4% among Veterans, which is five times higher than 
that of the general US population [1, 6]. In late 2013, VA providers began prescribing DAA 
medications in regimens to treat HCV infection. However, in August 2014, the Veterans 
Choice Program (Choice) was established and allowed eligible Veterans to receive health 
care, including HCV treatment, from a community provider rather than wait for a VA 
appointment or travel to a VA facility. Between November 2014 and January 2017, 1.5 
million Veterans representing 17% of all patients in VA care received care through Choice 
[7]. Accordingly, non-VA providers may have written prescriptions for HCV treatment during 
this time period. While it is plausible prescriptions of DAAs made off-site were filled by a VA 
pharmacy due to their high cost, it remains unclear if these Choice prescriptions and 
pharmacy fills are documented in the national VA Corporate Data Warehouse (CDW), the 
primary source of data for researchers. Additionally, electronic data from each VA facility go 
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through multiple extracts, transforms, and loads before reaching the CDW, all of which may 
compromise validity of the original data [8]. 
 
The purpose of this study was to compare DAA pharmacy fill records in CDW with facility-
level electronic health record (EHR) data at five VA sites with high HCV prevalence. We 
also sought to characterize the frequency of Choice prescriptions and their impact on the 
accuracy of CDW data in this sample. We hypothesized that we would find overall high 
agreement between data sources.   
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METHODS 
Design and data sources 
We conducted a retrospective cohort study among chronic HCV-infected patients in the 
Veterans Aging Cohort Study (VACS) between 1 January 2014 and 30 June 2016 [9, 10]. 
VACS consists of all HIV-infected patients receiving care at VA medical facilities across the 
US, matched to two HIV-uninfected patients on age, sex, race/ethnicity, and site. Available 
data include diagnoses, laboratory results, and pharmacy fill data from CDW as well as 
access to facility-level EHR information including electronic pharmacy records, clinical 
progress notes, and Choice referrals. For this analysis, we compared CDW pharmacy fill 
data with facility-level EHR data at five VA sites with high HCV prevalence (i.e., Atlanta, 
GA; Bronx, NY; Houston, TX; Los Angeles (LA), CA; Washington, DC). This study was 
approved by Institutional Review Boards of Yale University and each participating VACS 
site. 
 
Patients selected for validation 
All chronic HCV-infected patients (determined by positive HCV RNA) who had pharmacy fill 
data for HCV treatment in the CDW at any of the five VA sites between 1 January 2014 and 
30 June 2016 were eligible. We estimated that a target sample size of 500 patients would 
yield a minimal (≤4%) margin of error at any level of agreement >50% between CDW and 
facility EHR data. We included all patients treated for HCV infection at Atlanta (79) and LA 
(92) and randomly selected 110 patients from each remaining site. We also randomly 
selected 20 chronic HCV-infected patients at each site, without evidence of HCV treatment 
in CDW pharmacy data, to estimate frequency of HCV treatment not captured in CDW.  
 
HCV treatment agents 
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The original search for pharmacy fill data of HCV treatment in CDW occurred on 7 July 
2016, or seven days after the study period, and included the following DAA agents: 
boceprevir, telaprevir, simeprevir, sofosbuvir, daclatasvir, ledipasvir/sofosbuvir, 
ombitasvir/paritaprevir/ritonavir, ombitasvir/paritaprevir/ritonavir/dasabuvir, 
elbasvir/grazoprevir, sofosbuvir/velpatasvir (fixed-dose combinations indicated by / between 
medication names). We also evaluated for older HCV therapies, including interferon alfa-2a 
and -2b, pegylated interferon alfa-2a and -2b, and ribavirin. CDW data list each prescription 
of each agent or fixed-dose combination on a separate record. Therefore, an individual 
receiving a standard treatment of 12 weeks of ledipasvir/sofosbuvir, would have three 
records (one per 30-day fill) to validate. 
 
Confirmation of HCV Treatment 
For patients who received prescriptions for HCV treatment in CDW pharmacy fill data, we 
populated a validation database with name and date for each prescription found, including 
fill, release, return, and stop dates, and sent the encrypted database to each site. An 
experienced infectious disease (ID) physician at each facility was asked to confirm that 
each prescription was dispensed using the facility-level EHR.   
 
For patients without evidence of HCV treatment in CDW pharmacy fill data, ID physicians 
were asked to determine whether these patients had any evidence of receiving HCV 
treatment in the facility or outside the VA system during the study period based on a review 
of the facility EHR. For patients who received treatment outside VA (e.g., through Choice or 
other), details on their treatment (i.e., antiviral regimen prescribed, start and stop dates) 
were recorded.  
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Statistical analyses 
Demographic and clinical characteristics were compared across four distinct groups of 
patients: (1) treatment in CDW validated by EHR, (2) treatment in CDW not validated by 
EHR, (3) absence of treatment in CDW validated by EHR, and (4) absence of treatment in 
CDW not validated by EHR. For these comparisons, patients with treatment in CDW were 
deemed validated if all prescriptions were identified and not validated if at least one 
prescription was not identified. 
 
The primary outcome for patients with HCV treatment recorded in CDW was a patient-level 
indicator that denoted whether or not all pharmacy fill records for each patient were noted in 
the facility EHR. The primary outcome for sampled chronic HCV-infected patients without 
evidence of HCV treatment in CDW was a patient-level indicator that denoted any evidence 
of HCV treatment noted in the facility EHR, regardless of source of treatment. We 
calculated positive predictive value (PPV; proportion of patients with prescriptions in CDW 
that were validated) and negative predictive value (NPV; proportion of patients without 
prescriptions in CDW that were validated) with 95% confidence intervals (CIs) overall and 
by site. Lastly, we repeated the data extraction from CDW six months after the initial data 
pull to account for CDW data that may have been subsequently updated or corrected, and 
we re-calculated PPV and NPV. All statistical analyses were performed using SAS version 
9.4 (SAS Institute Inc., Cary, NC, USA). 
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RESULTS 
We reviewed facility-level EHR data from the original data extraction for 501 patients who 
had a combined 2,416 prescriptions for HCV treatment between 1 January 2014 and 30 
June 2016, as well as 100 patients without evidence of HCV treatment in CDW. The 
median age was 61 years (interquartile range [IQR] 58-64), 592 (98.5%) were male, 399 
(66.4%) were black/African-American, 124 (20.6%) were white, and 275 (45.8%) were HIV 
co-infected (Table 1).  
 
Table 1. Characteristics of chronic HCV-infected patients with and without evidence of pharmacy fill 
data for HCV treatment in the national Veterans Health Administration (VA) corporate data 
warehouse (CDW)  
 
Treatment in CDW 
 
Absence of treatment in 
CDW 
 
Validated Not validated 
 
Validated Not validated 
Characteristic n=493 n=8   n=97 n=3 
Age, years 
60.9 (58.0-
64.3) 
56.0 (53.4-
59.2)  
61.2 (57.6-
65.0) 
55.2 (51.7-
59.7) 
Male sex 488 (99.0) 8 (100.0) 
 
95 (97.9) 1 (33.3) 
Race/ethnicity 
     
     Black/African-American 327 (66.3) 3 (37.5) 
 
67 (69.1) 2 (66.7) 
     White 103 (20.9) 5 (62.5) 
 
15 (15.5) 1 (33.3) 
     Hispanic 51 (10.3) 0 (0) 
 
10 (10.3) 0 (0) 
     Other/unknown 12 (2.4) 0 (0) 
 
5 (5.2) 0 (0) 
HIV co-infection 230 (46.7) 2 (25.0)   43 (44.3) 0 (0) 
Abbreviations: HCV - hepatitis C virus; HIV - human immunodeficiency virus 
Note: continuous measures reported as median (interquartile range), categorical measures reported 
as n (%) 
 
Of 2,416 HCV prescriptions reviewed, 1,268 (52.1%) were ledipasvir/sofosbuvir, 399 
(16.4%) were ribavirin, 294 (12.1%) were sofosbuvir, 245 (10.1%) were 
ombitasvir/paritaprevir/ritonavir/dasabuvir, 159 (6.5%) were simeprevir, and the remaining 
medications included elbasvir/grazoprevir, daclatasvir, pegylated interferon, 
sofosbuvir/velpatasvir, boceprevir, and telaprevir. 
 
Overall, 493/501 patients (or 2,387/2,416 prescriptions) with evidence of treatment in CDW 
were validated yielding a PPV of 98.4% (95% confidence interval [CI] 97.3%-99.5%). 
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Across the five sites, PPVs ranged from 96.7% to 100% (p=0.60) (Table 2). Twelve (2.4%) 
patients received HCV care from a non-VA provider through Choice, and  all of their HCV 
prescriptions (n=34) were present in CDW. 
 
Table 2. Positive and negative predictive values of pharmacy fill data of HCV treatment in the 
national VA CDW  
 
Positive predictive value (PPV) 
 
Negative predictive value (NPV) 
Overall, % (95% CI) 98.4 (97.3, 99.5) 
 
97.0 (93.7, 100) 
By site 
     
     Atlanta 100 (100, 100) 
 
100 (100, 100) 
     Bronx 99.1 (97.3, 100) 
 
100 (100, 100) 
     DC 98.2 (95.7, 100) 
 
95.0 (85.5, 100) 
     Houston 98.2 (95.7, 100) 
 
90.0 (76.9, 100) 
     Los Angeles 96.7 (93.1, 100) 
 
100 (100, 100) 
  p=0.60   p=0.51 
Abbreviations: HCV - hepatitis C virus; VA - Veterans Health Administration; CDW - Corporate Data 
Warehouse; CI - confidence interval; DC - Washington, D.C. 
Note: Fisher’s Exact tests were used to test for heterogeneity across sites 
 
 
Of 100 patients without evidence of HCV treatment in CDW, 97 (97.0%) were confirmed not 
to have been treated and 3 (3.0%) were found to have received HCV treatment (22 
prescriptions, all within the VA) during the study period, resulting in an overall NPV of 
97.0% (95% CI 93.7%-100%). NPV results were similar across sites (p=0.51).  
 
After an updated data pull from CDW on 9 January 2017, or six months after the study 
period, one patient who was not originally validated among those treated in the CDW was 
found to agree with the facility-level report, and all but one of the 22 prescriptions were 
found for the three patients who originally had no treatment records in the CDW. These 
findings corresponded to an updated PPV of 98.6% (95% CI 97.6%-99.6%) and NPV of 
99.0% (95% CI 97.1%-100%).  
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DISCUSSION 
Our validation process suggests high levels of agreement between CDW and EHR data at 
five VA sites for 601 randomly selected VACS patients. The PPV among treated patients 
was 99% and the NPV among untreated patients was 97% from a data extraction one week 
after the study period. After repeated data extraction six months after the study period, PPV 
remained at 99% while NPV increased to 99%.  
 
There was modest utilisation of Choice in our sample. All HCV prescriptions that were 
ordered by a non-VA provider through Choice were captured in CDW. Providers found 
evidence of HCV treatment for three patients who had no evidence of HCV treatment in 
CDW, but their HCV care was received within the VA system and not through Choice. 
 
The sample used in this validation study had good representation of older patients, racial 
minorities, and those with HIV co-infection, which are underrepresented and often excluded 
populations in clinical trials of DAAs [11, 12].  
 
Our study had potential limitations. First, we chose five large VA sites with high HCV 
prevalence. Other VA sites that utilize Choice more frequently may not be represented. 
Second, there was a potential for bias arising from the study’s design that had site 
physicians validate a pre-populated list of medications found in CDW. However, this 
concern was minimized by the sole use of electronic data that did not burden physicians to 
search non-electronic (i.e., paper charts), as well as the detailed notes frequently added to 
the validation database by the experienced physicians. Finally, these findings may not be 
generalised to other national EHR systems, such as Medicare or Kaiser Permanente. 
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However, our methodology could be used to test validity of prescription fill data in other 
EHR systems. 
 
Observational data could serve an important role in pharmacoepidemiologic studies 
assessing safety and effectiveness of modern therapies for chronic HCV infection. These 
findings provide assurance to researchers who use national VA CDW data for retrospective 
cohort studies that the CDW contains accurate information, particularly after a six-month lag 
for data extraction, on HCV therapies in the modern treatment era, even for VA patients 
who obtained treatment from non-VA providers. Future analyses should examine 
comparative effectiveness of DAA regimens, adverse effects of importance (e.g., acute liver 
injury, HBV reactivation), and the impact of unhealthy alcohol use on receipt of DAAs and 
subsequent treatment outcomes. 
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